Dutogliptin tartrate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Dutogliptin tartrate
- Molecular weight
- 391.19
- Structure (SMILES)
- O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O.O=C(O)C(O)C(O)C(=O)O
- boronic acid 2r 1 3r 3 pyrrolidinylamino acetyl 2 pyrrolidinyl 2r 3r 2 3 dihydroxybutanedioate 1 1
- BORONIC ACID, ((2R)-1-(((3R)-3-PYRROLIDINYLAMINO)ACETYL)-2-PYRROLIDINYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
- dutogliptin tartrate
- Dutogliptin tartrate
- DUTOGLIPTIN TARTRATE [USAN]
- dutogliptin tartrate usan
- phx 1149
- PHX-1149
- phx1149t
- Phx1149t
- PHX1149T
- CAS registry numbers
- 890402-81-0
- ChEMBL ID
- CHEMBL4297203
- InChIKey
- SVWHNLVZPGXBNS-RJUBDTSPSA-N
- FDA ingredient codes (UNII)
- 79QH89EV9M
- 15949100
- 44198096
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -gliptin
Open Targets mechanisms
- Mechanism
- Dipeptidyl peptidase IV inhibitor
- Action type
- Inhibitor
- Target
- Dipeptidyl peptidase 4
Investigated indications
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
Open Targets indications
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- NCT00482950
- NCT00690638
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 27
- Molecular formula
- C14H26BN3O9
- Monoisotopic mass
- 391.1762096
- Natural product
- No
Related records
Trials (12)
- A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
- Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
- Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
- Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
- Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
- Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus
- Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
- Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
In development for (1)
- Type 2 diabetes mellitus Phase 3